Who are Ticagrelor orodispersible tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Group P+P, Prasugrel Oral Tablet, prasugrel or ticagrelor, clopidogrel napadisilate + aspirin, Group P+T, heparin + clopidogrel + aspirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ticagrelor-orodispersible-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ticagrelor orodispersible tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ticagrelor orodispersible tablets (Ticagrelor orodispersible tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist (antiplatelet agent). Area: Cardiovascular.

phase 3 P2Y12 receptor antagonist (antiplatelet agent) P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ticagrelor orodispersible tablets (Ticagrelor orodispersible tablets) — Azienda Ospedaliero Universitaria di Sassari. Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ticagrelor orodispersible tablets TARGET	Ticagrelor orodispersible tablets	Azienda Ospedaliero Universitaria di Sassari	phase 3	P2Y12 receptor antagonist (antiplatelet agent)	P2Y12 receptor
Group P+P	Group P+P	Huazhong University of Science and Technology	marketed	P2Y12 inhibitor	P2Y12 receptor
Prasugrel Oral Tablet	Prasugrel Oral Tablet	Elliot Israel, MD	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
prasugrel or ticagrelor	prasugrel or ticagrelor	University of Florida	marketed	P2Y12 receptor antagonist	P2Y12 receptor
clopidogrel napadisilate + aspirin	clopidogrel napadisilate + aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
Group P+T	Group P+T	Huazhong University of Science and Technology	marketed	P2Y12 inhibitor	P2Y12 receptor
heparin + clopidogrel + aspirin	heparin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Antiplatelet and anticoagulant combination	Thrombin, Factor Xa, Cyclooxygenase, P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist (antiplatelet agent) class)

Azienda Ospedaliero Universitaria di Sassari · 2 drugs in this class
Sheba Medical Center · 1 drug in this class
Sheffield Teaching Hospitals NHS Foundation Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticagrelor orodispersible tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/ticagrelor-orodispersible-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab